REIN THERAPEUTICS INC
RNTXNASDAQ🏆 #3239 by market capUS Equity
$0.82▲ $0.02 (+2.95%)
Market closed · at close1h—
24h▲ 3.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$70M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
51
Weak
No chart data available for RNTX.
Trading Snapshot
- Day Range
- $0.81 – $0.82
- 52-Week Range
- $0.69 – $2.18
- Volume
- $4.82B
- Avg Volume
- $4.80B
- Shares Outstanding
- 85.5M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.78
- Dividend Yield
- —
Why Investors Own RNTX
- ✓High-growth profile — revenue up +32.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5M▲ +31.1% YoY
Gross Margin (TTM)
35.8%▲ +2.3% YoY
Operating Income (TTM)
$1M▲ +31.1% YoY
Free Cash Flow (TTM)
$1M▲ +31.1% YoY
About REIN THERAPEUTICS INC
A company profile for REIN THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
51/100
Analyst Price Target
ⓘAverage Target
$1.05
▲ +28.2% Upside
High Target$1.25
Low Target$0.85
Based on 21 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
REIN THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift RNTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
REIN THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.